Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Eleanor Barnes et al.|The Lancet|2020Cited by 2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie Ewer, Megan Baker, Jordan R. Barrett et al.|Nature Medicine|2020Cited by 643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trialKalifa Bojang, Tom Doherty, Paul Milligan et al.|The Lancet|2001Cited by 528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet|2021Cited by 457
Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the GambiaMark Thursz, Adrian V. S. Hill, Dominic Kwiatkowski et al.|New England Journal of Medicine|1995Cited by 439